Cambridge Healthtech Institute’s 4th Annual
Bispecific Antibody Therapeutics
January 22-23, 2015
Creating bioactive molecules that are multivalent and multifunctional offers the promise of more effective therapeutics. By binding to at least two molecular targets simultaneously, antibodies are empowered, thereby delivering a highly potent therapeutic, particularly for cancer immunotherapy. This Bispecific Antibody Therapeutics conference explores the challenges of engineering multispecificity to ensure stability and efficacy, and reviews the numerous forms of multispecific antibodies. The conference gives particular focus to safety issues, as well as PK and immunogenicity. Case studies highlight preclinical development as well as clinical data.
Day 1 | Day 2 | Download
Brochure | Speaker Biographies
THURSDAY, JANUARY 22
11:30 am Conference Registration
12:30 pm Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own
1:30 Ice Cream Break in the Exhibit Hall with Poster Viewing
2:00 Chairperson’s Opening Remarks
Gunasekaran Kannan, Ph.D., Principal Scientist and Group Leader, Biologics Optimization, Amgen, Inc.
2:05 Cancer Immunotherapy with Bispecific T Cell Engager (BiTE®) Antibodies
Dirk Nagorsen, M.D., Ph.D., Global Development Leader, Global Clinical Development, Amgen Inc.
T cells are an important component of cancer immunosurveillance. Various approaches have been tested to use T cells for the treatment of malignant diseases. Bispecific T cell Engager (BiTE®) antibodies represent an innovative investigational approach that is designed to engage the body’s endogenous T cells to target malignant cells. This talk will give an overview of the development status of BiTE® antibodies including the most advanced molecule in this class, blinatumomab, which targets CD19 on malignant cells of B lineage.
2:45 A Novel Fc-Containing Bispecific Format with Full-Length Antibody Properties: Applications in Oncology
David Szymkowski, Ph.D., Senior Director, Biotherapeutics, Xencor, Inc.
Bispecific antibody development has been hindered by inferior stability, production and half-life. We have engineered the Fc domain to create bispecifics possessing full-length antibody properties, including excellent stability and manufacturability, and extended half-life. Xencor’s “XmAb®” candidates exploit a common anti-CD3 domain that recruits T cells to potently kill malignant cells. I will discuss our development of bispecific antibodies targeting several tumor antigens, including demonstration of safety and efficacy in monkeys.
3:15 Enhanced Tumor Cell Killing via Selective Inhibition of CD47 with Bispecific Antibodies
Nicolas Fischer, Ph.D., Head, Research, Novimmune SA
CD47 is a broadly expressed cell surface glycoprotein that is up regulated by tumour cells to evade surveillance by innate immune cells. We have generated and evaluated a panel of CD47xCD19 dual-targeting bispecific antibodies selectively inhibiting CD47 on tumour cells. Based on in vitro and in vivo experiments we have selected a lead therapeutic candidate that mediates effective tumour killing and has an appropriate pharmacokinetic profile in non human primates.
3:45 A New Platform to Automate Bispecific Antibody Design and Assessment
Christopher Smith, Ph.D., Senior Scientific Consultant, Biologics, Genedata
Next-generation antibodies, and specifically bispecifics, provide significant advantages over traditional IgG-based therapeutics. However, as highly engineered molecules they pose new design, cloning, expression, purification and analytics challenges. Our workflow platform fully automates the design, production and testing of large panels of multispecific antibody candidates, including tandem-scFv-Fc, KinH, DVD-Ig or diabodies. We demonstrate the platform’s handling of linkers, V-domains and Fc regions, its high-throughput capability and built-in tools for the systematic identification of development candidates based on a systematic analysis of assay, analytic and sequence data.
4:15 Refreshment Break in the Exhibit Hall with Poster Viewing
5:00 MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Adaptations in Growth Factor Signaling Networks
Alexey A. Lugovskoy, Ph.D., Vice President, Therapeutics; MM-141 Project Leader, Merrimack Pharmaceuticals, Inc.
Bispecific antibodies surpass the activity of conventional immunoglobulins and often possess added components of mechanisms of action. However, bispecifics have proven difficult to develop due to both suboptimal design and poor pharmaceutical properties. A Network Biology approach to drug design overcomes these complexities and accelerates the discovery of active and manufacturable therapeutic molecules. This approach will be illustrated by case studies of bispecific antibodies for the treatment of cancer developed at Merrimack Pharmaceuticals.
5:30 Therapeutic Fully Human Bispecific Antibodies with Two Binding Sites in Each Fv Region
Kristian Jensen, Ph.D., Vice President, Project Management, R&D, Dutalys GmbH
DutaMabs are fully human bispecific antibodies, comprising one normal heavy chain and one normal light chain, with two non-overlapping binding sites within the natural CDRs of each Fv. These two paratopes within the DutaMab CDRs are fully independent, due to an unprecedented stability, which exceeds that of all previously described antibodies. This allows the combination of any two specificities within one Fv, and their independent maturation to low pM affinities.
6:00-7:00 Reception at the Tiki Pavilion
Day 1 | Day 2 | Download
Brochure | Speaker Biographies